IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: A 26-week Asia-Pacific study
Yao, Wanzhen1; Wang, Changzheng2; Zhong, Nanshan3; Han, Xiaowen4; Wu, Changgui6; Yan, Xixin5; Chen, Ping7; Yang, Wei8; Henley, Michelle8; Kramer, Benjamin8
关键词Chinese chronic obstructive pulmonary disease efficacy indacaterol safety
刊名RESPIROLOGY
2014-02-01
DOI10.1111/resp.12211
19期:2页:231-238
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Respiratory System
资助者Novartis Pharma AG, Basel, Switzerland ; Novartis Pharma AG, Basel, Switzerland
研究领域[WOS]Respiratory System
关键词[WOS]AIR-FLOW OBSTRUCTION ; LUNG HYPERINFLATION ; DOUBLE-BLIND ; COPD ; EXERCISE ; EFFICACY ; BRONCHODILATORS ; SALMETEROL ; TIOTROPIUM ; TRIAL
英文摘要

Background and objectiveThis study, in a predominantly Chinese population, investigated the efficacy and safety of a once-daily (o.d.) inhaled ultra-long-acting (2)-agonist indacaterol for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD).

MethodsThis is a 26-week, double-blind study on randomized patients who received indacaterol 150g or 300g or placebo o.d. The primary variable was trough forced expiratory volume in 1s (FEV1, average of 23h 10min and 23h 45min post-dose values) at Week 12. Health status (St George′s Respiratory Questionnaire, SGRQ), dyspnoea (transition dyspnoea index, TDI) and safety were evaluated over 26 weeks.

ResultsOf the 563 patients randomized, 561 (89.8% Chinese) received treatment and 482 completed. At Week 12, trough FEV1 improved significantly for indacaterol 150 and 300g versus placebo (1.32, 1.29 vs 1.17; P<0.001 for both comparisons), with differences exceeding the pre-specified minimal clinically important difference of 0.12L. At Week 26, TDI score was superior to placebo for indacaterol 150 and 300g (0.82, 1.15; P<0.01), as was the percentage of patients with a clinically relevant improvement (1 point) (74.1%, 78.6% vs 55.5%; P<0.05). Both doses provided 4-point improvements from baseline in SGRQ score at Week 26 that were numerically greater than placebo (unadjusted means: -9.6, -8.8 vs -7.0), with a similar pattern in percentage of patients with clinically relevant improvements in SGRQ score (65.0%, 61.5% vs 60.6%). Incidences of adverse events were comparable across treatment groups.

ConclusionsIndacaterol delivered effective bronchodilation with significant improvements in breathlessness and health status in this predominantly Chinese population.

We investigated the effect of indacaterol on FEV1, dyspnoea and health-related quality of life in a predominantly Chinese population diagnosed with moderate-to-severe COPD. Indacaterol proved to be a useful treatment option as it showed effective bronchodilation and improvements in breathlessness and health status in this population.

语种英语
资助者Novartis Pharma AG, Basel, Switzerland ; Novartis Pharma AG, Basel, Switzerland
WOS记录号WOS:000330798700013
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61479
专题北京大学第三临床医学院
作者单位1.Peking Univ, Hosp 3, Beijing 100083, Peoples R China
2.Guangzhou Inst Resp Dis, Guangzhou, Guangdong, Peoples R China
3.Peoples Hosp Hebei Prov, Shijiazhuang, Peoples R China
4.Hebei Med Univ, Hosp 2, Shijiazhuang, Peoples R China
5.Xijing Hosp, Dept Resp Med, Xian, Peoples R China
6.Novartis Pharmaceut, E Hanover, NJ USA
7.Third Mil Med Univ, Xingiao Hosp, Chongqing, Peoples R China
8.Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China
推荐引用方式
GB/T 7714
Yao, Wanzhen,Wang, Changzheng,Zhong, Nanshan,et al. Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: A 26-week Asia-Pacific study[J]. RESPIROLOGY,2014,19(2):231-238.
APA Yao, Wanzhen.,Wang, Changzheng.,Zhong, Nanshan.,Han, Xiaowen.,Wu, Changgui.,...&Kramer, Benjamin.(2014).Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: A 26-week Asia-Pacific study.RESPIROLOGY,19(2),231-238.
MLA Yao, Wanzhen,et al."Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: A 26-week Asia-Pacific study".RESPIROLOGY 19.2(2014):231-238.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yao, Wanzhen]的文章
[Wang, Changzheng]的文章
[Zhong, Nanshan]的文章
百度学术
百度学术中相似的文章
[Yao, Wanzhen]的文章
[Wang, Changzheng]的文章
[Zhong, Nanshan]的文章
必应学术
必应学术中相似的文章
[Yao, Wanzhen]的文章
[Wang, Changzheng]的文章
[Zhong, Nanshan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。